IL101773A - Isochlorine hypertonic preparation for the treatment of shock - Google Patents

Isochlorine hypertonic preparation for the treatment of shock

Info

Publication number: IL101773A
Authority: IL; Israel
Prior art keywords: pharmaceutical composition; osmolar; composition; sodium chloride; concentration
Prior art date: 1991-05-31

Application number

IL10177392A

Other languages

English (en)

Hebrew (he)

Other versions

IL101773A0 (en

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-31

Filing date

1992-05-04

Publication date

1996-06-18

1992-05-04 Application filed by Univ Texas filed Critical Univ Texas

1992-12-30 Publication of IL101773A0 publication Critical patent/IL101773A0/xx

1996-06-18 Publication of IL101773A publication Critical patent/IL101773A/en

Links

239000000203 mixture Substances 0.000 title claims description 36
230000005796 circulatory shock Effects 0.000 title claims description 16
238000009472 formulation Methods 0.000 title description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 110
239000011780 sodium chloride Substances 0.000 claims abstract description 55
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 34
239000001632 sodium acetate Substances 0.000 claims abstract description 33
235000017281 sodium acetate Nutrition 0.000 claims abstract description 33
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
230000004872 arterial blood pressure Effects 0.000 claims abstract description 25
239000012530 fluid Substances 0.000 claims abstract description 23
210000000056 organ Anatomy 0.000 claims abstract description 16
239000000243 solution Substances 0.000 claims description 34
208000032843 Hemorrhage Diseases 0.000 claims description 32
238000001802 infusion Methods 0.000 claims description 18
239000000084 colloidal system Substances 0.000 claims description 14
229920002307 Dextran Polymers 0.000 claims description 13
238000002637 fluid replacement therapy Methods 0.000 claims description 11
230000036284 oxygen consumption Effects 0.000 claims description 9
206010021137 Hypovolaemia Diseases 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
229920002472 Starch Polymers 0.000 claims description 6
235000019698 starch Nutrition 0.000 claims description 6
108010010803 Gelatin Proteins 0.000 claims description 4
206010021138 Hypovolaemic shock Diseases 0.000 claims description 4
229920000159 gelatin Polymers 0.000 claims description 4
235000019322 gelatine Nutrition 0.000 claims description 4
235000011852 gelatine desserts Nutrition 0.000 claims description 4
206010040560 shock Diseases 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 3
229920001612 Hydroxyethyl starch Polymers 0.000 claims description 3
206010020751 Hypersensitivity Diseases 0.000 claims description 3
206010040047 Sepsis Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
208000030961 allergic reaction Diseases 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
230000008081 blood perfusion Effects 0.000 claims description 2
239000011777 magnesium Substances 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
235000018102 proteins Nutrition 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
229910052751 metal Inorganic materials 0.000 claims 2
239000002184 metal Substances 0.000 claims 2
230000000977 initiatory effect Effects 0.000 claims 1
229910052742 iron Inorganic materials 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000012047 saturated solution Substances 0.000 claims 1
150000003751 zinc Chemical class 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 24
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 14
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 14
229910052760 oxygen Inorganic materials 0.000 abstract description 14
239000001301 oxygen Substances 0.000 abstract description 14
208000032456 Hemorrhagic Shock Diseases 0.000 abstract description 3
206010049771 Shock haemorrhagic Diseases 0.000 abstract description 3
238000011282 treatment Methods 0.000 description 25
230000000747 cardiac effect Effects 0.000 description 19
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
241000282472 Canis lupus familiaris Species 0.000 description 16
230000000740 bleeding effect Effects 0.000 description 16
230000017531 blood circulation Effects 0.000 description 12
230000036772 blood pressure Effects 0.000 description 7
208000010444 Acidosis Diseases 0.000 description 5
206010060964 Arterial haemorrhage Diseases 0.000 description 5
230000007950 acidosis Effects 0.000 description 5
208000026545 acidosis disease Diseases 0.000 description 5
208000014674 injury Diseases 0.000 description 5
230000035939 shock Effects 0.000 description 5
230000008733 trauma Effects 0.000 description 5
210000001367 artery Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
239000000819 hypertonic solution Substances 0.000 description 3
229940021223 hypertonic solution Drugs 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
229910001415 sodium ion Inorganic materials 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000002792 vascular Effects 0.000 description 3
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
206010000489 Acidosis hyperchloraemic Diseases 0.000 description 2
208000002881 Colic Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
230000000703 anti-shock Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
230000009084 cardiovascular function Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
229940119743 dextran 70 Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
238000010606 normalization Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241001631457 Cannula Species 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020955 Hypochloraemia Diseases 0.000 description 1
208000019025 Hypokalemia Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010030124 Oedema peripheral Diseases 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
208000036064 Surgical Blood Loss Diseases 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
230000000758 acidotic effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000011257 definitive treatment Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
238000011833 dog model Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229940027278 hetastarch Drugs 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000013627 low molecular weight specie Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
208000024896 potassium deficiency disease Diseases 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
108010001708 stroma free hemoglobin Proteins 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

IL10177392A 1991-05-31 1992-05-04 Isochlorine hypertonic preparation for the treatment of shock IL101773A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/708,029 US5248507A (en)	1991-05-31	1991-05-31	Hypertonic isochloremic formulation for circulatory shock

Publications (2)

Publication Number	Publication Date
IL101773A0 IL101773A0 (en)	1992-12-30
IL101773A true IL101773A (en)	1996-06-18

Family

ID=24844101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10177392A IL101773A (en)	1991-05-31	1992-05-04	Isochlorine hypertonic preparation for the treatment of shock

Country Status (9)

Country	Link
US (2)	US5248507A (fr)
EP (1)	EP0587815B1 (fr)
JP (1)	JPH0714882B2 (fr)
AT (1)	ATE168009T1 (fr)
AU (1)	AU654720B2 (fr)
CA (1)	CA2103246A1 (fr)
DE (1)	DE69226184T2 (fr)
IL (1)	IL101773A (fr)
WO (1)	WO1992021356A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5416078A (en) *	1990-03-30	1995-05-16	Biomedical Frontiers, Inc.	Fluid resuscitation
US5248507A (en) *	1991-05-31	1993-09-28	Board Of Regents, The University Of Texas System	Hypertonic isochloremic formulation for circulatory shock
US6017953A (en) *	1993-12-28	2000-01-25	Allergan Sales, Inc.	Thromboxane ligands
US6566326B1 (en) *	1996-03-13	2003-05-20	The Regents Of The University Of California	Chemically modified hemoglobin for burn shock resuscitation
WO1998008500A1 (fr) *	1996-08-26	1998-03-05	Board Of Regents, The University Of Texas System	Compositions hypertoniques d'arginine et procedes
CN1068778C (zh) *	1998-05-15	2001-07-25	赵超英	救治用的药物组合物及其制备方法
GB0011202D0 (en)	2000-05-09	2000-06-28	Kci Licensing Inc	Abdominal wound dressing
DE60109184T2 (de) *	2000-10-16	2005-12-29	Universite De Liege	Medizinische zusammensetzung und insbesondere seine verwendung in der flüssigkeitstherapie
DE602004002585T2 (de) *	2003-05-01	2007-10-25	Innogene Kalbiotech Pte. Ltd.	Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen
US20050100637A1 (en) *	2003-11-12	2005-05-12	Robert Murray	Carbohydrate and electrolyte replacement composition
EP2007371A4 (fr) *	2006-04-03	2009-07-22	Innogene Kalbiotech Pte Ltd	Composition pharmaceutique contenant du lactate et du calcium et leurs utilisations
US8551075B2 (en)	2006-06-02	2013-10-08	Kci Medical Resources	Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing
WO2007142688A1 (fr)	2006-06-02	2007-12-13	Bengtson Bradley P	Ensembles, systèmes et procédés pour un drainage interne assisté par dépression pendant la guérison d'une lésion
US7699831B2 (en)	2006-06-02	2010-04-20	Surgical Design Solutions, Llc	Assemblies, systems, and methods for vacuum assisted internal drainage during wound healing
CN101164530B (zh) *	2006-10-18	2010-10-20	周方强	含稳定的丙酮酸钠的水溶液及其制法和用途
CN107865985B (zh)	2008-09-18	2023-04-28	3M创新知识产权公司	用于控制炎症反应的系统和方法
EP2340065B1 (fr)	2008-10-29	2015-08-12	KCI Licensing, Inc.	Systèmes et procédés de fermeture de tissu profond sous pression réduite
US8216197B2 (en)	2008-10-29	2012-07-10	Kci Licensing, Inc	Medical canister connectors
US8435590B2 (en) *	2008-11-24	2013-05-07	Stokely-Van Camp, Inc.	Use of novel carbohydrates and carbohydrate blends to provide a sports beverage with increased absorption
WO2011112166A1 (fr) *	2010-03-12	2011-09-15	Scott Cordray	Méthode de traitement
EP2382993A1 (fr)	2010-04-19	2011-11-02	KTB Tumorforschungsgesellschaft mbH	Combinaison de médicaments avec pro-médicaments à liaison de protéines
CN103830166B (zh) *	2012-11-22	2015-07-15	北京四环制药有限公司	一种高渗复苏液的制备方法及其应用
US10124021B2 (en)	2016-12-23	2018-11-13	Andrew L. Gostine	Intravenous fluid
US12419850B1 (en)	2024-03-21	2025-09-23	GanD, Inc.	Bioactive fluid compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4049795A (en) *	1971-05-14	1977-09-20	Centre D'etudes Experimentales Et Cliniques De Physio Biologie De Pharmacologie Et D'eutonologie	Treatment of hemorrhagic shock
US3993750A (en) *	1974-12-20	1976-11-23	Research Corporation	Aqueous hypertonic solution and compositions useful for preparation of same
US4908350A (en) *	1985-10-31	1990-03-13	The Regents Of The University Of California	Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock
US4927806A (en) *	1987-04-23	1990-05-22	The Regents Of The University Of California	Saturated salt/concentrated dextran formulation to treat hemorrhage
US5248507A (en) *	1991-05-31	1993-09-28	Board Of Regents, The University Of Texas System	Hypertonic isochloremic formulation for circulatory shock

1991
- 1991-05-31 US US07/708,029 patent/US5248507A/en not_active Expired - Fee Related
1992
- 1992-04-27 AT AT92917365T patent/ATE168009T1/de not_active IP Right Cessation
- 1992-04-27 EP EP92917365A patent/EP0587815B1/fr not_active Expired - Lifetime
- 1992-04-27 AU AU18728/92A patent/AU654720B2/en not_active Ceased
- 1992-04-27 CA CA002103246A patent/CA2103246A1/fr not_active Abandoned
- 1992-04-27 WO PCT/US1992/003489 patent/WO1992021356A1/fr not_active Ceased
- 1992-04-27 JP JP4510340A patent/JPH0714882B2/ja not_active Expired - Lifetime
- 1992-04-27 DE DE69226184T patent/DE69226184T2/de not_active Expired - Fee Related
- 1992-05-04 IL IL10177392A patent/IL101773A/en not_active IP Right Cessation
1993
- 1993-09-24 US US08/126,242 patent/US5443848A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US5443848A (en)	1995-08-22
JPH0714882B2 (ja)	1995-02-22
ATE168009T1 (de)	1998-07-15
EP0587815A1 (fr)	1994-03-23
DE69226184T2 (de)	1999-04-08
EP0587815B1 (fr)	1998-07-08
WO1992021356A1 (fr)	1992-12-10
DE69226184D1 (de)	1998-08-13
CA2103246A1 (fr)	1992-12-01
US5248507A (en)	1993-09-28
JPH06500130A (ja)	1994-01-06
AU654720B2 (en)	1994-11-17
AU1872892A (en)	1993-01-08
IL101773A0 (en)	1992-12-30

Legal Events

Date	Code	Title
1996-11-14	FF	Patent granted
1997-02-18	KB	Patent renewed
1998-11-26	KB	Patent renewed
2002-06-30	KB	Patent renewed
2007-02-12	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0587815B1 (fr)	1998-07-08	Composition isochloremique hypertonique pour le traitement des chocs circulatoires
JP5037937B2 (ja)	2012-10-03	乳酸塩含有医薬組成物及びその使用
US5945272A (en)	1999-08-31	Plasma expanders and blood substitutes
Goodin et al.	1994	A perfluorochemical emulsion for prehospital resuscitation of experimental hemorrhagic shock: a prospective, randomized, controlled study
US7754247B2 (en)	2010-07-13	Resuscitation fluid
US20090285909A1 (en)	2009-11-19	Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
Ratner et al.	1993	Intraoperative fluid management
JPH05507709A (ja)	1993-11-04	血中ナトリウム値無変化救急蘇生のための高張液
Pantaleon	2010	Fluid therapy in equine patients: small-volume fluid resuscitation
Neligan	2025	Crystalloids, colloids, blood and blood products and substitutes
Williams et al.	2022	Fluid Therapy
KR20120046160A (ko)	2012-05-09	혈장-적합 균형 젤라틴 용액
WO2000069427A1 (fr)	2000-11-23	Traitement de l'ischemie des membres et composition a cet effet
Moran	1999	Albumin and resuscitation: a sense of Deja Vu
NZ572358A (en)	2011-03-31	Lactate and calcium containing pharmaceutical composition and uses thereof
Vincent et al.	1989	Crystalloids versus colloids in septic shock